Cellectis (XPAR:ALCLS) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALCLS Cellectis SA XPAR:ALCLS
56 GF Score
Price €1.31
GF Value €2.74
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cellectis Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

XPAR:ALCLS
56GF Score
Cellectis SA XPAR:ALCLS
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cellectis (XPAR:ALCLS) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be undervalued. The current stock price of €1.31 is trading 52.2% below its estimated GF Value™ of €2.74. GuruFocus considers Cellectis to be Possible Value Trap.

Key valuation signals for XPAR:ALCLS:

  • Dividends Received:
  • GF Value™: €2.74 vs. price of €1.31 (52.2% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALCLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
56GF Score

Get the complete analysis for XPAR:ALCLS

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price
€2.74
GF Value